Broadening Therapeutic Indications to Cancers with Lower Target Antigen Expression with C’Dot Drug Conjugates
Time: 4:15 pm
day: Conference Day Two
Details:
- C’Dot Drug Conjugates (CDCs) are a platform technology that is associated with specific tumor targeting/low normal tissue exposure
- CDCs have the potential to target and kill tumors with lower antigen expression than is normally possible with ADCs
- Clinical efficacy and safety data will be presented from the safety/dose escalation study of ELU001
